Skip to main content

Advertisement

Fig. 2 | BMC Medical Research Methodology

Fig. 2

From: How do researchers determine the difference to be detected in superiority trials? Results of a survey from a panel of researchers

Fig. 2

Distribution of the differences to be detected for death or cancer recurrence between the new treatment and its comparator selected by respondents in vignette 2 when: a the risk of death of cancer recurrence was 10 % in patients with reference treatment (low baseline risk) (n = 183), b the risk of death of cancer recurrence was 60 % in patients with reference treatment (high baseline risk) (n = 170). The difference between the percentage selected by a respondent and the baseline risk is the difference to be detected

Back to article page